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2001; Achermann and Borbely, 2003; Saper et al., 2005). These 
homeostatic and circadian factors govern a complex, yet partially 
deﬁ  ned, balance between sub-cortical excitatory and inhibitory 
neural populations in the brain (Pace-Schott and Hobson, 2002; 
Fort et al., 2009). Although these wake- and sleep-active neurons 
are distributed throughout the brain, most of the wake-promoting 
neurons are found in restricted brain areas including the brainstem, 
the hypothalamus and the basal forebrain. Interestingly, relatively 
few sleep-active nuclei have been discovered, mostly restricted to 
the lateral hypothalamus and preoptic area.
Brain arousal and sleep centers contain overlapping neuronal 
and non-neuronal cell types of different chemical composition and 
electrical properties (Gerashchenko and Shiromani, 2004), that 
may inﬂ  uence the sleep–wake cycle and sleep-dependent processes 
(Halassa et al., 2009). This heterogeneity has severely hampered 
our ability to record from and manipulate the neural dynamics 
of sleep and wake circuitry. For example, using a microelectrode 
to record or stimulate neural activity in brain regions known 
to promote sleep or wakefulness is incredibly difﬁ  cult or even 
impossible given the 3D architecture of some neural populations 
spread out over millimeters, even in small rodents. Furthermore, 
the presence of multiple cell types that overlap within the same 
volume of tissue prevents an electrode from selectively stimulating 
speciﬁ  c cells of interest. New technology is clearly needed to estab-
lish causal, functional relationships between identiﬁ  ed sleep- and 
wake- promoting neural circuits and how these circuits interact to 
govern the sleep/wake cycle.
We have recently used a new technology called optogenetics to 
selectively stimulate or inhibit speciﬁ  c neural circuits in the brain. 
Optogenetic tools combine the temporal precision of a microelec-
trode with the spatial precision of a genetically encodable probe, 
allowing the stimulation or inhibition of complete populations of 
INTRODUCTION
Sleep is commonly deﬁ  ned as “a rapidly reversible state of (behav-
ioral) immobility and greatly reduced sensory responsiveness to envi-
ronmental stimuli” (Siegel, 2008). Although the parameters of the 
sleep–wake cycle vary within and between species, all animals show 
rest-activity patterns or sleep-like states. In addition to mammalian, 
reptilian, and avian species, recent studies report the existence of 
“sleep-like” states in lower organisms including the ﬁ  sh, ﬂ  y, and 
worm (Shaw et al., 2000; Yokogawa et al., 2007; Allada and Siegel, 
2008; Raizen et al., 2008; Zimmerman et al., 2008).
In mammals, there are three states of vigilance: wakefulness, 
slow-wave sleep (also called non-rapid eye movement “NREM” 
sleep), and rapid eye movement (REM) sleep, deﬁ  ned by electroen-
cephalographic (EEG) and electromyographic criteria. Wakefulness 
consists of fast EEG oscillations (5–12 Hz) of low amplitude with 
frequent and sustained motor activity. NREM sleep is characterized 
by slow oscillations (1–4 Hz) of high amplitude and can be divided 
into four stages in human (two in rats, one in mice), corresponding 
to increasing depth of sleep. REM sleep is characterized by relatively 
fast oscillations (6–12 Hz) of low amplitude and persistent muscle 
atonia. REM sleep has also been coined “paradoxical sleep” due to 
the simultaneous occurrence of cortical activity similar to wakeful-
ness and a lack of a muscle tone (Jouvet, 1965).
Sleep naturally follows a period of wakefulness. Prolonging the 
wake period increases the propensity to sleep, revealing a homeo-
statically regulated process (Borbely, 1982, 2001). In addition to 
homeostatic drive, sleep is regulated by circadian rhythms, which 
determine the timing of sleep, as well as other physiological vari-
ables including core body temperature and production of hor-
mones (such as cortisol or melatonin). Thus, sleep homeostasis 
and circadian rhythms both inﬂ  uence the ultradian processes 
that governs the architecture of the sleep–wake cycle (Borbely, 
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speciﬁ  c neuronal subtypes. This technology has allowed us to gain 
insight into a population of wake-promoting neurons, hypocretin 
neurons, and has the potential to answer multiple questions about 
many other neural populations, as well as the sleep/wake cycle as 
a whole.
Here, we review the neural substrates of sleep and wakefulness in 
small and large mammals. These neural circuits have been identiﬁ  ed 
and studied throughout the past few decades using a combination of 
histological, pharmacological, genetic, and in vitro and in vivo elec-
trophysiology techniques. We focus on the use of these tools to study 
the hypocretin system, demonstrating the strengths and limitations 
of traditional electrophysiological and transgenic technologies. Then, 
we describe the use of optogenetic technology to probe the function 
of the hypocretin system in sleep regulation and how it has allowed us 
to make progress in our understanding of the role of these neurons 
in vivo. Finally, we propose to use optogenetics as a fundamental tool 
to investigate the necessity, sufﬁ  ciency, and connectivity of deﬁ  ned 
neural circuits in the regulation of sleep and wakefulness.
SLEEP–WAKE CIRCUITS OF THE BRAIN
The neural substrates of sleep-to-wake transitions are governed by 
distinct neural populations in the brain. Activity in these nuclei is 
correlated with wakefulness: not only does their activity increase 
when an animal is awake compared to asleep, but this activity also 
increases during states of enhanced arousal, such as moments of 
high alertness or stress. These arousal systems include:
•  The noradrenergic locus coeruleus (LC), located in the pon-
tine brainstem (Aston-Jones and Bloom, 1981)
•  The neuropeptide S cells, located in the pontine brainstem (Xu 
et al., 2004)
•  The serotinergic raphe neurons, located in the medial brain-
stem (McGinty and Harper, 1976; Guzman-Marin et al., 2000; 
Sakai and Crochet, 2000)
•  The dopaminergic neurons in the ventral mesencephalic mid-
brain (Dahan et al., 2007) and the brainstem (Lu et al., 2006)
•  The histaminergic tuberomammillary nucleus, located in the 
posterior hypothalamus (Parmentier et  al., 2002; Takahashi 
et al., 2006)
•  The hypocretin neurons, located in the lateral hypothalamus 
(Peyron et al., 2000; Lee et al., 2005; Mileykovskiy et al., 2005)
•  The cholinergic neurons, located in the basal forebrain 
(Hassani et al., 2009a) and pontine brainstem.
These arousal centers each send widespread ascending projec-
tions to the cerebral cortex, stimulating cortical desynchronization 
characterized by high frequency gamma and low frequency theta 
rhythmic activity (Steriade et al., 1993).
In addition, these systems have descending projections that 
enhance or modulate muscle tone, sensory-motor responsiveness, 
and physiological activity. These multiple arousal systems show 
obvious redundancy, since triple lesions of the main arousal cent-
ers in the brain (basal forebrain, tuberomammillary nucleus, LC) 
have no major effect of the architecture of the sleep–wake cycle 
(Blanco-Centurion et al., 2007), yet they can be differentiated based 
on their unique activity patterns throughout the sleep–wake cycle, 
as well as their contribution to other complex behaviors (such as 
food and drug seeking behaviors, attention, decision making, and 
the response to stress). During sleep, they are under an inhibitory 
tone from sleep-active neurons.
In contrast to the multiple, redundant arousal systems, there 
are relatively few identiﬁ  ed sleep-promoting neural populations. 
These nuclei were identiﬁ  ed on the basis of immunoreactivity to 
the immediate early gene c-Fos – a biomarker of neuronal  activity –, 
single unit recordings, neurotoxic lesions, neurochemical, and 
  thermal stimulation studies. Sleep-promoting nuclei include: the 
ventrolateral preoptic area (VLPO), located in the preoptic area and 
the median preoptic nucleus (MnPN), located in the preoptic area 
(Alam et al., 1995; Gallopin et al., 2000; Lu et al., 2002; McGinty 
et al., 2004).
Both the VLPO and MnPN neuronal populations express 
GABA, and send descending projections to arousal-promoting 
cell groups. Thus, they may inhibit noradrenergic, serotonergic, 
cholinergic, histaminergic and hypocretinergic neurons, as sug-
gested by the “reciprocal inhibitory” model of the sleep–wake switch 
(Pace-Schott and Hobson, 2002; McGinty and Szymusiak, 2003) 
as recently suggested by Suntsova et al. (2007). The role of these 
neurons in promoting or maintaining sleep is not well understood 
and will require future investigation.
Brain structures responsible for REM sleep onset and mainte-
nance were ﬁ  rst identiﬁ  ed in the brainstem in the pericoeruleus 
region in cats using a physical lesion approach (Jouvet and Michel, 
1959; Fort et al., 2009) and many neurons in this brain area are selec-
tively active during REM sleep (Sakai et al., 2001). According to the 
“reciprocal-interaction model”, noradrenergic and serotonergic, his-
taminergic and hypocretin (Hcrt) neurons cease ﬁ  ring during REM 
sleep (Aston-Jones and Bloom, 1981; Lee et al., 2005; Mileykovskiy 
et al., 2005; Takahashi et al., 2006). Finally, pericoeruleus cholinergic 
and GABAergic neurons located in the dorsal paragigantocellular 
reticular nucleus (DPGi) and the ventrolateral periaqueductal gray 
have recently been identiﬁ  ed as additional neuronal populations 
regulating the onset and maintenance of REM sleep events (Jones, 
2004); Pace-Schott, 2002 #17; Fort, 2009 #3122.
Recent studies identiﬁ  ed additional sleep modulating neuronal 
populations in the brain (Verret et al., 2003; Gerashchenko et al., 
2008; Hassani et al., 2009b). One of those includes the hypotha-
lamic neurons expressing the melanin-concentrating hormone 
(MCH) that are active mainly during REM sleep (Verret et al., 2003; 
Hassani et al., 2009b). However, contrasting results from experi-
mental approaches using different techniques (immunodetection 
of c-Fos, pharmacology, knockout mouse models) are found in the 
literature (Verret et al., 2003; Modirrousta et al., 2005; Adamantidis 
et al., 2008; Willie et al., 2008).
In addition to classical neurotransmitters and neuropep-
tides described above, numerous endogenous factors modulate 
sleep, including prostaglandin D2 (Ueno et al., 1982; Scammell 
et al., 1998), adenosine (Virus et  al., 1983; Porkka-Heiskanen 
et al., 1997), growth hormone-releasing hormone and interleukins 
(Krueger et al., 1999; Kushikata et al., 1999), all of which also have 
other physiological functions.
Now that we have examined the key components of the neural 
circuitry modulating sleep and wake states, we focus on the hypo-
cretin system as an example of how sleep nuclei are studied and 
manipulated during experiments.Frontiers in Molecular Neuroscience  www.frontiersin.org  January 2010  | Volume 2  |  Article 31  |  3
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THE HYPOCRETIN SYSTEM AS A MODULATOR OF THE SLEEP–
WAKE CYCLE
In 1998, two groups independently reported a novel pair of neu-
ropeptides called the Hcrts (also known as “orexins”) exclusively 
expressed in a population of glutamatergic neurons in the lateral 
hypothalamus. These neuropeptides are cleaved from the same 
genetic precursor (preprohypocretin) (de Lecea et al., 1998; Sakurai 
et al., 1998). There are two hypocretin receptors (Hcrtrs) distrib-
uted throughout multiple brain areas that match the afferent ﬁ  ber 
projections from Hcrt neurons. The projection pattern of afferent 
projections and receptor expression suggests that the Hcrt system 
is involved in multiple brain function (Sakurai, 2007).
Hypocretin neurons are activated by neurotransmitters that 
promote arousal including glutamate (Li et al., 2002; Yamanaka 
et al., 2003), CRF (Winsky-Sommerer et al., 2004), ATP (Wollmann 
et al., 2005), noradrenaline and charbachol (acethycholine agonist) 
(Bayer et al., 2005), A subpopulation of Hcrt neurons are activated 
by Ach (Sakurai et al., 2005). Importantly, sleep-promoting neu-
rotransmitters inhibit Hcrt neurons, including GABA (through 
GABAa,b; Li et al., 2002; Yamanaka et al., 2003; Xie et al., 2006), and 
adenosine (A1) (Liu and Gao, 2007).
In the 10 years since their discovery, much has been learned 
about the Hcrt system by correlating neural activity with behavioral 
output, as well as gain-of-function and loss-of-function   studies. 
Experiments that manipulate Hcrt function typically involve 
 pharmacology, in which an agonist or antagonist (or Hcrt peptides 
themselves) are injected into the ventricular system or discrete brain 
regions. Alternatively, many studies employ genetic manipulation of 
the Hcrt system using transgenic or knockout technologies in the 
mouse. We brieﬂ  y summarize these studies below.
CORRELATION BETWEEN HCRT NEURAL ACTIVITIES AND 
BEHAVIORAL STATES
Recently, technically challenging in vivo single unit recordings of 
identiﬁ  ed Hcrt neurons conﬁ  rmed their high discharge activity 
during arousal, including behavior accompanied with a strong loco-
motor activity (Lee et al., 2005; Mileykovskiy et al., 2005; Takahashi 
et al., 2008). In contrast to their oscillatory activity in brain slices 
(Eggermann et al., 2003), Hcrt neurons are completely silent during 
quiet wakefulness, NREM and REM sleep and are reactivated dur-
ing REM sleep-to-wake transitions (Lee et al., 2005; Mileykovskiy 
et al., 2005).
GAIN-OF-FUNCTION STUDIES
Many gain-of-function studies have been applied to the lateral hypoth-
alamus as a whole. In addition to promoting food intake (Anand and 
Brobeck, 1951; Bernardis and Bellinger, 1996), electrical stimulation 
of lateral hypothalamic region decreased REM sleep duration in rats 
and cats (Suntsova et al., 2000), possibly through a Hcrt-mediated 
inhibition of neurons in the oral nucleus of the pons (Dergacheva 
et al., 2005; Nunez et al., 2006), which is an important structure in 
the generation and maintenance of REM sleep. Disinhibition of LH 
cells by GABAA antagonists (bicuculline or gabazine ) injections into 
the LH area induced a continuous quiet waking state associated with 
a robust muscle tone in head-restrained rats (Goutagny et al., 2005), 
partly via activation of Hcrt neurons (Lu et al., 2007). However, none 
of these approaches have selectively targeted the Hcrt system.
Other studies used icv infusion of hcrt peptides or hcrt  agonists 
(Akanmu and Honda, 2005), as well as local injection of the pep-
tide in the LC (Bourgin et al., 2000), LH (Methippara et al., 2000), 
laterodorsal tegmental nucleus (Xi et al., 2001), basal forebrain 
structures (Espana et  al., 2001), in rodents and cats enhanced 
wakefulness and locomotor activity which was accompanied by a 
marked reduction in REM and non-REM sleep. Local Hcrt1 injec-
tions in cholinergic nuclei of the pons (nucleus pontis oralis) have 
promoted wakefulness, suppressed SWS and “defacilitated” REM 
sleep, whereas it directly inhibited REM sleep when injected in the 
ventral part of the NPO vs RPO (Xi et al., 2002; Moreno-Balandran 
et al., 2008; Watson et al., 2008). Interestingly, Hcrt administration 
can reverse behavioral attacks in narcoleptic dogs (see below) (John 
et al., 2000; Fujiki et al., 2003). More recently, genetic disinhibition 
of Hcrt neurons using a selective GABAB receptor gene deletion 
only in Hcrt neurons in mice were found to induce severe fragmen-
tation of sleep/wake states during both the light and dark periods, 
without showing an abnormality in total sleep time or signs of 
cataplexy (Matsuki et al., 2009).
LOSS-OF-FUNCTION STUDIES
Although electrical or chemical anatomical lesions of the LH (the 
“lateral hypothalamic syndrome”) are not speciﬁ  c to the arousal-
promoting Hcrt neurons, such lesions were reported to induced 
aphagia and adipsia for several days during which they showed a 
disorganized EEG characterized by rapid low voltage activity and 
high voltage low frequency waves (Danguir and Nicolaidis, 1980). 
Sleep increased gradually and normal amounts of both NREM and 
REM sleep was observed during “stage 4” of recovery, when rats 
eat and drink as normal.
Other lesional studies found that extensive LH lesions caused 
either insomnia (Trojniar et al., 1990; Jurkowlaniec et al., 1996) or 
transient hypersomnia (Denoyer et al., 1991) with disturbed hip-
pocampal theta activity both during waking and paradoxical sleep 
(Jurkowlaniec et al., 1989) in rodents and cats. In human, patients 
with cataplexy (Schwartz et al., 1984), disrupted temporal pattern-
ing of the sleep–wake cycle (Cohen and Albers, 1991) and increased 
total sleep time (Eisensehr et al., 2003) have been reported second-
ary to a surgical lesion that involved the perichiasmal, the rostral 
hypothalamus, or bilateral posterior hypothalamus, respectively.
To selectively target Hcrt-responsive neurons, saporin-coupled 
Hcrt molecules were used to suppress Hcrt neurons in vivo. Saporin 
is a ribosome inactivating protein that kills target cells once inter-
nalized. Thus, the use of saporin toxin conjugated to the Hcrtr bind-
ing ligand, Hcrt2, lesions Hcrtr-expressing neurons. This has the 
effect of inducing sleep when injected into the LH (Gerashchenko 
et al., 2001, 2003) independently of adenosine levels in the basal 
forebrain (Murillo-Rodriguez et al., 2008) and insomnia when 
injected in the VTA and substantia nigra (Gerashchenko et al., 
2006). Unfortunately, saporin alone has toxic properties on Hcrt 
neurons themselves, thus constituting weak control conditions.
Hypocretin receptor antagonists have been used to target the 
Hcrt system with receptor selectivity. Blockade of Hcrt-2R is sufﬁ  -
cient to initiate and prolong sleep and co-administration of Hcrt-1R 
with Hcrt-2R antagonists greatly attenuated the sleep-promoting 
effects of the Hcrt2R antagonist (Dugovic et al., 2009). Hcrt-R1 
antagonist delays emergence from anesthesia, without changing Frontiers in Molecular Neuroscience  www.frontiersin.org  January 2010  | Volume 2  |  Article 31  |  4
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anesthetic induction (Kelz et al., 2008). Dual Hcrt receptor antago-
nists increased both non-REM and REM sleep in rats (Whitman 
et al., 2009), somnolence and increased surrogate markers of REM 
sleep in dogs, and electrophysiological signs of sleep in human 
(Brisbare-Roch et al., 2007). However, these antagonists differ in 
their afﬁ  nities for HcrtR-1 and HcrtR-2. Additionally, they may, at 
very low binding concentrations, modulate other receptors when 
administered in vivo.
The most signiﬁ  cant loss-of-function studies demonstrate that 
deﬁ  ciency of the Hcrt system is linked to narcolepsy in humans 
(Peyron et al., 2000), dogs (Lin et al., 1999) and mice (Chemelli et al., 
1999; Blumberg et al., 2007). Narcoleptic patients with cataplexy 
have non- or barely-detectable levels of Hcrt in the cerebro-spinal 
ﬂ  uid, in addition to the absence of preproHcrt gene transcripts in 
the hypothalamus (Peyron et al., 2000). Doberman narcoleptic dogs 
bear a mutation in Hcrt-R2, and all genetically engineered rodents 
with either a deletion of the Hcrt (Chemelli et al., 1999; Hunsley 
et al., 2006; Blumberg et al., 2007), HcrtR-2 gene (Willie et al., 2003) 
or Hcrt cells (Beuckmann et al., 2004; Zhang et al., 2007b; Fujiki 
et al., 2009) present behavioral arrests that resemble cataplexy, the 
hallmark of narcolepsy. However, HcrtR-2 KO mice are less affected 
with cataplexy-like attacks of REM sleep compared to Hcrt KO mice 
that are more severely affected (Willie et al., 2003), suggesting that 
the altered REM sleep control in narcolepsy-cataplexy syndrome 
emerges from loss of signaling through both HcrtR-2-dependent 
and Hcrt-R2-independent pathways (Willie et al., 2003). Finally, 
alternative approaches to genetic technologies include the use of 
short interfering RNAs (siRNA) targeting prepro-orexin mRNA. 
Once injected into the rat LH, animals exhibited a transient increase 
in REM sleep (few days) compared to scrambled siRNA-treated 
animals (Chen et al., 2006).
Collectively, these studies support a role for the Hcrt system 
in “lowering the arousal treshold” (Sutcliffe and de Lecea, 2002), 
resulting in a facilitation of wakefulness when animal are asleep. 
Furthermore, the ability of Hcrts to modulate the reward system of 
the brain (Boutrel and de Lecea, 2008) also suggest that it could pro-
mote hyperarousal (deﬁ  ned as a transient, hyper-alertness state trig-
gered by salient stress or reward) when the animal is awake (DiLeone 
et al., 2003; Winsky-Sommerer et al., 2004; Boutrel et al., 2005).
NOVEL METHODS OF MANIPULATING Hcrt NEURONS
Selectively stimulating or inhibiting Hcrt function represents 
the next step in understanding Hcrt cell function. Although the 
studies mentioned above provide substantial evidence for the role 
of Hcrt neurons in promoting wakefulness and arousal, the 3D 
architecture of the Hcrt ﬁ  eld, as well as the heterogeniety of cell 
types found in the lateral hypothalamus, have imposed limitations 
using traditional microstimulation or pharmacological techniques 
to perform loss-of-function or gain-of function studies. Indeed, in 
addition to non-neuronal cells, lateral hypothalamic cells include 
neurons expressing MCH, CRF, TRH, substance P or Neurotensin 
(Gerashchenko and Shiromani, 2004). The most common way of 
inducing electrical activity in neurons for the past century has been 
injecting current through a microelectrode (Figure 1A). Although 
temporally precise, a microelectrode cannot distinguish between 
cell types in the stimulated area. Furthermore, it may inadvert-
ently stimulate other, unintended regions that are adjacent to the 
 electrode. Pharmacological techniques lack both spatial and tempo-
ral precision, as psychoactive substances can spread throughout the 
brain and require minutes to hours to clear the system (Bittencourt 
and Sawchenko, 2000) (Figure 1A). Modern biochemical tech-
niques, such as the delivery of photosensitive “caged glutamate” 
to neurons, improve upon the spatial and temporal properties of 
pharmacological methods. However, restriction of the caged gluta-
mate to speciﬁ  c neurons of interest cannot be guaranteed, and 
the time-course of photostimulation is on the order of seconds to 
minutes. It is possible to deliver genetically encodable probes to 
neurons that can be activated to depolarize discrete subsets of neu-
rons. For example, speciﬁ  c targeting of a ligand-gated ion channel 
that is not normally expressed in the brain may help to stimulate 
neural activity by just adding its selective ligand. Unfortunately, this 
strategy has a poor temporal resolution, as endogenous ligand must 
be added and then eventually cleared from the local area of interest. 
Finally, the crudest method of silencing Hcrt neural activity in the 
brain has been to ablate these neurons, either physically with a sharp 
instrument, pharmacologically with a toxin, or genetically with a 
genetically encodable toxin. Of course, these non-reversible lesions 
cause a total loss of neural function, with no chance for recovery.
Recently, our lab has employed optogenetic technology 
(Deisseroth et al., 2006) to selectively manipulate the Hcrt system 
in vivo (Figure 1B). Optogenetics can be thought of as a perfect 
combination of an electrode, which has high temporal precision, 
with a genetically encodable probe, which has high spatial res-
olution. Genetic delivery of a light-sensitive ion channel called 
  channelrhodopsin-2 (ChR2) (Nagel et  al., 2003) into speciﬁ  c 
populations of neurons can be used to stimulate neural activity 
upon illumination in several animal species including rodents and 
non-human primates (Boyden et al., 2005; Li et al., 2005; Lima and 
Miesenbock, 2005; Nagel et al., 2005; Ishizuka et al., 2006; Schroll 
et al., 2006; Adamantidis et al., 2007; Arenkiel et al., 2007; Petreanu 
et al., 2007; Wang et al., 2007; Huber et al., 2008; Gradinaru et al., 
2009; Han et al., 2009a; Tsai et al., 2009). This channel is naturally 
expressed in green algae and normally absent in animals. Because 
ChR2 is genetically encoded, speciﬁ  c promoter and enhancer ele-
ments can be used to express the channel in discrete populations 
of neurons in the brain. Then, ChR2-expressing neurons can be 
activated by delivering blue light using thin ﬁ  ber-optic cables, 
implanted into the brain for long-term experiments over days or 
weeks (Adamantidis et al., 2007; Aravanis et al., 2007).
Alternatively, a separate light-sensitive protein, Halorhodopsin 
(NpHR), naturally expressed by archaebacteria and normally 
absent in animals, has been recently used to inhibit neural activity. 
NpHR is a chloride pump that hyperpolarizes neurons (and thus 
inhibits neural activity) upon stimulation with yellow light (Han 
and Boyden, 2007; Zhang et al., 2007a; Gradinaru et al., 2008; Han 
et al., 2009b). Importantly, ChR2 and NpHR both have a tempo-
ral resolution of milliseconds, allowing stimulation or silencing of 
single action potentials. Thus, optogenetic technology allows for 
temporally precise manipulation of speciﬁ  c populations of neurons 
in an awake, behaving animal.
In an attempt to better understand the role of Hcrt neurons on 
arousal, we used optogenetics to study the effect of Hcrt neuronal 
activation on SWS and REM sleep transitions to wakefulness. First, 
we genetically targeted the light-activated channel ChR2 to Hcrt Frontiers in Molecular Neuroscience  www.frontiersin.org  January 2010  | Volume 2  |  Article 31  |  5
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FIGURE 1 | Comparison between electrical/pharmacological activation or 
inhibition and optogenetic activation of Hcrt neurons in the lateral 
hypothalamus. 2D architecture of the Hcrt ﬁ  eld showing the heterogeniety of 
cell types found in the lateral hypothalamus, including MCH, Hcrt, 
corticotropin-releasing factor (CRF), NPY/AgRP , POMC/CART, growth 
hormone-releasing hormone (GHRH), growth hormone (GH), neurotensin 
(NT), and substance P . Note that, in addition to these deﬁ  ned cell types, the 
hypothalamus contain glutamatergic and GABAergic neurons. For clarity, 
Nesfatin-1, thyrotropin-releasing hormone (TRH), vasopressin and oxytocin are 
not represented. (A) Limitations of traditional microstimulation or 
pharmacological techniques to perform loss-of-function or gain-of function 
studies include confounding effect on neuronal and non-neuronal cells 
surrounding the tarted cells. For instance, infusion of Hcrt peptide or 
non-peptide agonists or antagonists can spread up to 1000 µm away from the 
infusion site, therefore activating or inhibiting several neuronal populations in 
addition to the Hcrt neurons. Alternatively, temporally precise microelectrode 
stimulation cannot distinguish between cell types in the stimulated area, and 
thus may inadvertently stimulate other, unintended regions that are adjacent 
to the electrode. Concentric circles represent distance (in µm) from possible 
injection, stimulation or lesion site. (B) Optogenetic technology allow selective 
stimulation (using ChR2) or inhbition (using NpHR) of genetically targeted Hcrt 
neurons, with no confounding modulation of surrounding cells that may 
regulate the same brain function.
to express ChR2. Therefore, deep brain optical stimulation activated 
only the Hcrt neurons and not the surrounding cells. Second, the 
fast ON–OFF kinetics (i.e., millisecond timescale) of ChR2 were 
found to induce single action potentials in brain slices in ChR2-
expressing Hcrt neurons. Deep brain delivery of high frequency 
light pulse trains were found to activate Hcrt neurons (as measured 
by c-Fos immunohistochemistry) in vivo. Importantly, the mil-
lisecond timescale temporal resolution mimicked the physiologi-
cal range of neuronal spiking rate, overcoming the limitations of 
previous techniques (e.g., uncontrolled persistence of Hcrt peptide 
in the brain after local infusion).
We found that direct, deep brain optical stimulation of hypo-
cretin neurons in the hypothalamus increased the probability 
of transitions to wakefulness from either NREM or REM sleep 
(Adamantidis et  al., 2007). Interestingly, photostimulation 
using 5–30 Hz light pulse trains reduced latency to wakefulness, 
whereas 1 Hz trains did not. We also asked whether Hcrt-medi-
ated sleep-to-wake transitions are affected by light/dark period 
and sleep pressure. We found that stimulation of Hcrt neurons 
increased the probability of an awakening event throughout the 
entire light/dark period but that this effect was diminished with 
sleep pressure induced by 2 or 4 h of sleep deprivation (Carter 
et al., 2009). These results suggest that the Hcrt system promotes 
wakefulness throughout the light/dark period by activating mul-
tiple downstream targets, which themselves are inhibited with 
increased sleep pressure. Finally, stimulation of Hcrt neurons was 
still sufﬁ  cient to increase the probability of an awakening event in 
histidine decarboxylase-deﬁ  cient knockout animals, suggesting 
that histamine neurons of the TMN are not the main downstream 
target of Hcrt-mediated increase of arousal, as suggested by other 
studies (Carter et al., 2009). These studies demonstrate that we 
now have the right tools to establish causal links between fre-
quency-dependent activation of restricted neuronal population 
and speciﬁ  c behavioral state transitions.
PERSPECTIVES
A series of recent ﬁ  ndings has begun to identify the important 
neuroanatomical substrates of sleep and wakefulness. However, 
important questions remain unanswered about how the brain 
integrates homeostatic sleep pressure and circadian rhythms at 
the neuronal circuit level. For example,
•  Are known neural populations (e.g., catecholaminergic, nora-
drenergic neurons) sufﬁ  cient or permissive to promote either 
sleep, wakefulness or state transitions?
•  What are the kinetics of neurotransmission between sleep- 
and wake-promoting circuits in the brain in an unrestrained, 
behaving animal?
•  What are the consequences of neurotransmitter vs neuropep-
tide release from synapses of sleep- or wake-promoting cir-
cuits on the sleep–wake cycle and associated brain functions 
(e.g., metabolism, cognition, brain plasticity)?
Addressing these questions or probing other neural circuits will 
require genetic targeting of optogenetic tools to speciﬁ  c neuronal 
populations. Current targeting technologies include the identiﬁ  ca-
tion of minimal promoters compatible with viral-based approaches 
neurons using a well-characterized Hcrt speciﬁ  c promoter in a 
lentiviral delivery system (Adamantidis et al., 2007). Although the 
lentivirus infected multiple hypothalamic cells types, only the cells 
with the endogenous cellular machinery to express Hcrt were found Frontiers in Molecular Neuroscience  www.frontiersin.org  January 2010  | Volume 2  |  Article 31  |  6
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(Adamantidis et al., 2007) and Cre-assisted transgenic tools (Atasoy 
et al., 2008; Tsai et al., 2009). Over the next several years, it will 
be important to use these different targeting strategies to apply 
optogenetic studies to neural populations implicated in sleep/wake 
circuitry. It will also be interesting to apply optogenetic manipu-
lation to multiple sleep–wake populations to investigate circuit 
interactions and stimulate, for example, Hcrt neurons while simul-
taneously inhibiting other cell populations in order to determine 
their necessity in Hcrt-mediated sleep-to-wake transitions.
Current light delivery methods to activate optogenetic tools 
include optical ﬁ  bers coupled to pulsed lasers or light emitted diodes. 
These methods of light delivery should be customized for the speciﬁ  c 
experiment (e.g. cortical or deep brainstimulation, unilateral or bilat-
eral stimulation, etc.). It is currently difﬁ  cult to target diffuse struc-
tures, such as the hippocampus or cerebral cortex. However, future 
tools may allow light delivery to large-scale neuronal structures.
Novel, synergistic combinations of recently-developed 
approaches (Sjulson and Miesenbock, 2008), including in vivo 
optogenetics, genetic tagging of neural circuits (e.g., brainbow 
technology) (Livet et  al., 2007), optogenetic assisted neural 
  circuit mapping (Petreanu et al., 2007, 2009; Atasoy et al., 2008) 
and in vivo state-of-the-art imaging techniques now can address 
the questions raised above. This will expand the experimental 
possibilities available and allow in vivo deconstruction of pre-
viously inaccessible genetically deﬁ  ned sleep–wake neuronal 
circuits located in the hypothalamus, basal forebrain and brain-
stem with temporal and spatial resolutions relevant to physi-
ological dynamics. These approaches will help to understand 
the function of sleep and identify new therapeutical targets to 
cure sleep disorders and sleep-  associated neuropsychiatric dis-
orders, including metabolic imbalance, mood-related pathology 
and cognitive impairment.
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